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Background: Vitamin D has pleiotropic effects important for the proper func-
tioning of multiple organ systems. We investigated whether serum 25-
hydroxyvitamin D [25(OH)D] levels inﬂuenced hospitalization-free survival in
patients with chronic kidney disease (CKD).
Methods: In this prospective study, serum levels of 25(OH)D were measured in 210
patients with CKD in the winter of 2009. Data regarding hospitalizations were
collected over the subsequent 3 years.
Results: Vitamin D deﬁciency, as deﬁned by a serum 25(OH)D level below 15 ng/
mL, was observed in 76.7% of the patients. The mean 25(OH)D serum level was
13.6 ± 7.8 ng/mL in predialysis patients (n ¼ 62) and 11.3 ± 6.7 ng/mL in dialysis
patients (n ¼ 148). During the follow-up, 107 patients (28 predialysis and 79 dial-
ysis) were hospitalized because of infectious (33.6%) or cardiovascular diseases
(23.4%). Predialysis and dialysis groups were divided into 2 subgroups based on the
median 25(OH)D serum level. KaplaneMeier analysis revealed that the risk of
hospitalization was signiﬁcantly lower in both predialysis and dialysis patients with
above-median serum 25(OH)D levels (log-rank test; P ¼ 0.043 and 0.002,
respectively). Multivariate Cox proportional hazards models also demonstrated that
the risk of hospitalization was signiﬁcantly lower for patients with higher serum
25(OH)D levels in both the predialysis (hazard ratio, 0.963; 95% conﬁdence inter-
val, 0.93e0.99) and dialysis groups (hazard ratio, 0.955; 95% conﬁdence interval,
0.91e0.99).
Conclusion: A lower serum 25(OH)D level predicted poorer hospitalization-free
survival in both predialysis and dialysis CKD patients.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Internal Medicine, CHA
9 Yatap-ro, Bundang-gu,
ng), ysy0119@cha.ac.kr
ty of Nephrology. Published b
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Vitamin D is a pleiotropic vitamin with roles in bone and
mineral metabolism [1,2] and immunomodulation [3] and has
been reported to have antitumoral activity [4] and be involved
in renal [5] and cardiovascular protection [6,7]. Low 25-
hydroxyvitamin D [25(OH)D] levels are associated withy Elsevier. This is an open access article under the CC BY-NC-ND license
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(CKD) [8e10] and the general population [11,12]. In addition,
vitamin D receptor (VDR) activator therapy is associated with
lower mortality in CKD patients [8e10,13]. This improved
prognosis is mainly attributed to the preventive effects of VDR
activator against death caused by cardiovascular disease,
whereas a few reports have indicated that it can prevent death
from infections [14].
Cardiovascular disease and infection are the ﬁrst and second
leading causes of morbidity andmortality in patients with CKD,
respectively [14e16]. Care of patients with CKD is associated
with substantial costs to society, much of which is accounted
for by a high rate of hospitalization [17].
Patients with chronic renal failure are typically vitamin D
deﬁcient [18e21]. However, few studies have investigated the
relationship between vitamin D deﬁciency and hospitalization
in patients with CKD.
The aim of this prospective studywas to investigatewhether
the serum 25(OH)D level inﬂuences hospitalization-free sur-
vival in predialysis and chronic hemodialysis patients.
Methods
Study population
We recruited adult outpatients from Bundang CHA General
Hospital. A total of 210 adult patients with CKDwere enrolled in
our study. Criteria for inclusion were age 20e90 years and a
conﬁrmed diagnosis of CKD [deﬁned as being on dialysis or
having 2 previously estimated glomerular ﬁltration rate (eGFR)
values <60 mL/min/1.73 m2 calculated according to the equa-
tion of the Modiﬁcation of Diet in Renal Disease Study Group
and obtained at an interval of 3e6 months]. Patients were
categorized according to the CKD stage and Kidney Disease
Outcomes Quality Initiative guidelines [22]. Patients catego-
rized as CKD Stage 5D were on hemodialysis 3 times/wk
(>12 h/wk) for at least 3 months without exposure to renal
transplantation. Patients with acute infectious diseases, un-
stable vital signs, or neoplastic illness were excluded. None of
the participants were on active vitamin D, vitamin D analogues,
warfarin, steroids, or anticonvulsants during the month before
study entry. All patients provided written informed consent
and participated during the winter period.
Measurements
Bodymass indexwas calculated as bodyweight in kilograms
divided by height in meters squared. Blood pressure was
measured after 15 minutes of recumbency. Pulse pressure (PP)
was calculated using the formula: PP ¼ SBP e DBP, where SBP
and DBP are systolic and diastolic blood pressures, respectively.
Arterial stiffness was assessed using a commercially available
device (VP-2000; Colin, Komaki, Japan) for brachial-ankle pulse
wave velocity (baPWV) measurements. Pulse wave forms were
obtained from the brachial and posttibial artery after 15 mi-
nutes of recumbency [23]. Pulse wave velocity was calculated
as the distance between 2 arterial recording sites divided by
transit time, as described previously [23]. The mean baPWV of
the right and left sides was obtained in predialysis patients, and
1-side baPWV from 1 arm without arteriovenous access was
analyzed in hemodialysis patients. Measurements were ob-
tained before the last hemodialysis of the week in chronichemodialysis patients. All measurements were performed by a
single investigator who was blinded to the clinical data,
including the participants' CKD status.
Blood chemistry
All blood chemistry measurements were determined with
samples drawn before the hemodynamic study and included
serum albumin, serum high-sensitive C-reactive protein, blood
lipid, serum phosphate, and calcium levels. Serum calciumwas
adjusted for serum albumin. The total intact parathyroid (iPTH)
hormone level was evaluated by an electrochemiluminescence
immunoassay. Serum levels of 25(OH)D2 þ D3 were measured
using a chemiluminescent immunoassay (LIAISON; DiaSorin,
Saluggia, Italy). Levels of 1,25(OH)2D3 were determined using
an 125I radioimmunoassay (DiaSorin). On the basis of
previously published studies, vitamin D deﬁciency was
considered at serum 25(OH)D levels <15 ng/mL, vitamin D
insufﬁciency at levels of 15e30 ng/mL, and vitamin D
adequacy at serum levels >30 ng/mL [21].
Clinical outcome: hospitalization-free survival
We prospectively observed all hospitalization events, mor-
tality, and kidney transplantation over a 3-year follow-up
period. Hospitalization was deﬁned as any hospitalization
event, regardless of cause of admission, with more than 1
overnight stay. The causes of hospitalization were classiﬁed as
infectious and/or inﬂammatory, cardiovascular, cerebrovascu-
lar, gastrointestinal bleeding, or other bymedical record review
or telephone contact. The outcome for this analysis was time to
hospitalization from any cause.
Statistical analysis
Continuous variables are expressed as means± standard
deviation and categorical variables as frequencies. For univar-
iate analysis, the unpaired Student's t test, analysis of variance,
or the c2 test was used, depending on the characteristics of the
variables. Pearson's correlation coefﬁcients were used to sum-
marize the cross-sectional relationship among biochemical,
clinical, and 25(OH)D levels. Predialysis and dialysis groups
were divided into 2 subgroups based on the median 25(OH)D
serum level. 25(OH)D was analyzed as a categorical variable to
characterize the pattern of the relationship between each
exposure and clinical outcome. The KaplaneMeier method and
Cox proportional hazard models were also used to investigate
the inﬂuence of each factor on hospitalization-free survival in
predialysis and dialysis patients. A value of P < 0.05 was
considered signiﬁcant. Statistical analyses were performed
with SPSS for Windows (version 17; SPSS, Chicago, IL, USA).
Results
Patient characteristics and prevalence of vitamin D
deﬁciency
Baseline clinical and biochemical characteristics are shown
in Table 1. Of the patients studied, 29.5% were predialysis pa-
tients and their eGFR was 29.7 ± 15.4 mL/min/1.73 m2. Of these
patients, 20.3% were Stage 3, 35.9% were Stage 4, and 17.2%
were Stage 5. Chronic hemodialysis patients comprised 70.5% of
Table 1. Baseline characteristics of the study cohort
Characteristics Predialysis Dialysis
Patients 62 (29.5) 148 (70.5)
Age (y) 61.7 ± 12.3 57.0 ± 12.7
Men 62.5 48.0
Diabetes 50.0 48.6
BMI (kg/m2) 24.2 ± 3.3 24.4 ± 3.6
Previous CVD 21.9 39.9
Coronary 4.3 18.2
Cerebrovascular 17.2 27.1
Peripheral VD 4.3 12.2
MDRD-4 (mL/min/1.73 m2) 29.7 ± 15.4 6.3 ± 6.3
SBP (mmHg) 135.6 ± 20.2 145.3 ± 25.2
PP (mmHg) 55.8 ± 13.4 62.6 ± 16.6
BaPWV (m/s) 17.3 ± 4.5 18.4 ± 4.3
WBC (103/mL) 6.3 ± 2.0 6.3 ± 2.0
Hemoglobin (g/dL) 11.5 ± 1.6 10.5 ± 2.7
Albumin (g/dL) 4.2 ± 0.4 3.9 ± 0.4
BUN (mg/dL) 37.8 ± 19.8 63.9 ± 21.1
Calcium (mg/dL) 9.1 ± 0.6 9.2 ± 0.9
Phosphate (mg/dL) 3.5 ± 0.7 4.8 ± 1.7
iPTH (pg/dL) 96.8 ± 123.9 178.6 ± 252.3
CRP (mg/dL) 0.2 ± 0.4 0.5 ± 1.5
1,25(OH)2D (ng/mL) 31.1 ± 13.9 22.5 ± 8.5
25(OH)D (ng/mL) 13.6 ± 7.8 11.3 ± 6.7
Normal (>30 ng/mL) 3.2 2.0
Insufﬁciency (15e30 ng/mL) 29.0 17.6
Deﬁciency (<15 ng/mL) 67.6 80.4
Medications
ACEi/ARBs 85.2 84.0
Statin 48.4 45.3
Ca-containing P-binder 14.1 73.0
Data are presented as means ± SD or number of observations (%).
1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D;
ACEi, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II
receptor blockers; BaPWV, brachial-ankle pulse wave velocity; BMI,
body mass index; BUN, blood urea nitrogen; Ca-containing P-binder,
calcium-containing phosphate binder; CRP, C-reactive protein; CVD,
cardiovascular disease; iPTH, intact parathyroid hormone; MDRD-4,
estimated glomerular ﬁltration rate estimated by Modiﬁcation of Diet
in Renal Disease formula; PP, pulse pressure; SBP, systolic blood pres-
sure; VD, vascular disease; WBC, white blood cell.
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52.9± 47.7 months. The mean Kt/V of chronic hemodialysis
patients was 1.4 ± 0.4. The mean 25(OH)D serum level was
13.6 ± 7.8 ng/mL in predialysis patients and 11.3 ± 6.7 ng/mL in
dialysis patients. Most of the patients had vitamin D deﬁciency
(67.6% and 80.4% of predialysis and dialysis patients, respec-
tively), and only a few patients had an adequate vitamin D level
(3.2% and 2.0% of predialysis and dialysis patients, respectively;
Table 1).Differences in patient characteristics according to the serum
25(OH)D level
Analysis using Pearson's correlation coefﬁcient revealed an
inverse correlation between the serum 25(OH)D level and
blood urea nitrogen (BUN; r ¼ e0.27, P ¼ 0.037), serum creat-
inine (r ¼ e0.256, P ¼ 0.045), phosphate (r ¼ e0.33, P ¼ 0.008),
and alkaline phosphatase (r ¼ e0.40, P ¼ 0.028), whereas there
were direct correlations between the serum 25(OH)D level and
hemoglobin (r ¼ 0.33, P ¼ 0.012) and eGFR (r¼ 0.29, P ¼ 0.023)
in predialysis patients. However, only the total CO2 level
(r¼ 0.20, P ¼ 0.014) was positively correlated with the serum
25(OH)D level in dialysis patients.Predialysis and dialysis groups were divided into 2 sub-
groups based on the median 25(OH)D serum level (Table 2).
There were more women than menwith 25(OH)D levels below
the median among both predialysis (P ¼ 0.008) and dialysis
patients (P < 0.001). Predialysis patients with a 25(OH)D serum
level below the median had a lower eGFR, higher levels of BUN
and iPTH, and lower hemoglobin and phosphate levels than
patients with a higher 25(OH)D serum level (P < 0.001). Among
dialysis patients, there was a greater percentage of diabetes
patients in the group with 25(OH)D levels below the median
than the group with 25(OH)D levels above the median. How-
ever, in contrast to predialysis patients, there were no signiﬁ-
cant differences in the level of phosphate, iPTH, BUN,
hemoglobin, or eGFR between the groups with serum 25(OH)D
levels above or below the median in dialysis patients.
Serum 25(OH)D level and risk of hospitalization
One hundred seven patients (28 predialysis and 79 dialysis)
were hospitalized, 24 patients died (2 predialysis and 22 dial-
ysis), and 4 patients underwent kidney transplantation during
the 3-year observational period. Mean observational period
was 1,048.8 ± 331.0 days. Causes of hospitalization events
included infection-related disease (33.6%), cardiovascular dis-
ease (23.4%), and cerebrovascular disease (7.5%; Table 3). Most
common causes of death were cardiovascular disease (37.5%)
and infection-related disease (29.2%).
Hospitalization-free survival according to the level of serum
25(OH)D in predialysis and dialysis patients is shown in Fig. 1.
KaplaneMeier analysis revealed that the risk of hospitalization
was signiﬁcantly lower in both predialysis and dialysis patients
with above-median serum 25(OH)D levels (log-rank test;
P¼ 0.030 and 0.006, respectively). In univariate Cox propor-
tional analysis, serum 25(OH)D level, diabetes, coronary dis-
ease, eGFR, hemoglobin level, and phosphate level were
signiﬁcant predictors of all-cause hospitalization in predialysis
patients. In contrast, low serum 25(OH)D level, age, sex, and
diabetes were signiﬁcant predictors of hospitalization in dial-
ysis patients (Table 4). After adjustment for all related covari-
ables (sex, diabetes, coronary disease, eGFR, hemoglobin level,
phosphate level, and iPTH level for predialysis patients and age,
sex, and diabetes for dialysis patients), multivariate Cox pro-
portional hazards models demonstrated that the risk of hos-
pitalization was signiﬁcantly lower for patients with above-
median serum 25(OH)D levels in both the predialysis (hazard
ratio, 0.963; 95% conﬁdence interval, 0.93e0.99) and dialysis
groups (hazard ratio, 0.955; 95% conﬁdence interval,
0.91e0.99; Table 5).
Discussion
We demonstrated a high prevalence of 25(OH)D deﬁciency
and insufﬁciency in predialysis and dialysis patients. Most
importantly, a low serum 25(OH)D level predicted poor
hospitalization-free survival in CKD patients with or without
hemodialysis.
CKD is an increasing global health problem because of the
high risk of total and cardiovascular morbidity and mortality. In
the United States, the prevalence estimate of CKD increased
from 12.3% to 14.0% over the past 20 years [24]. Similarly, in
Korea, the prevalence of end stage renal disease requiring
dialysis increased by approximately ~8e9% per year during the
Table 2. Comparison of clinical laboratory variables between subgroups based on median 25(OH)D serum levels
Characteristics Predialysis patients Dialysis patients
25(OH)D 11.8 25(OH)D <11.8 P 25(OH)D 9.6 25(OH)D <9.6 P
Patients 31 (50.0) 31 (50.0) e 73 (49.3) 75 (50.7) e
Age (y) 62.6 ± 11.9 60.8 ± 12.8 0.581 57.0 ± 12.2 57.1 ± 13.2 0.780
Men 80.6 48.4 0.008 69.9 34.7 < 0.001
Diabetes 41.9 61.3 0.130 37.0 60.0 0.005
BMI (kg/m2) 24.5 ± 2.8 23.9 ± 3.7 0.485 22.6 ± 3.0 21.9 ± 3.4 0.203
Previous CVD 22.6 22.6 1.000 42.5 37.3 0.525
Coronary 3.2 3.2 1.000 13.7 22.7 0.159
Cerebrovascular 19.4 16.1 0.742 32.9 21.3 0.115
Peripheral VD 3.2 6.5 0.557 8.3 16.0 0.158
MDRD-4 (mL/min/1.73 m2) 37.5 ± 15.2 23.8 ± 13.2 0.002 6.4 ± 5.9 6.1 ± 6.7 0.819
SBP (mmHg) 131.2 ± 20.1 139.9 ± 19.6 0.100 145.8 ± 26.7 144.9 ± 23.7 0.843
PP (mmHg) 52.5 ± 13.0 58.9 ± 13.2 0.067 62.1 ± 18.5 63.2 ± 14.6 0.688
BaPWV (m/s) 16.8 ± 4.0 17.9 ± 4.8 0.342 17.9 ± 4.0 19.0 ± 4.6 0.144
WBC (103/mL) 6.2 ± 1.6 6.5 ± 2.4 0.659 6.1 ± 1.9 6.5 ± 2.1 0.182
Hemoglobin (g/dL) 12.0 ± 1.7 11.0 ± 1.3 0.011 10.1 ± 0.9 10.9 ± 3.4 0.081
Albumin (g/dL) 4.4 ± 0.3 4.1 ± 0.5 0.057 4.0 ± 0.3 3.9 ± 0.4 0.215
BUN (mg/dL) 31.1 ± 14.7 44.4 ± 22.0 0.007 65.7 ± 18.1 62.3 ± 23.6 0.346
Calcium (mg/dL) 9.1 ± 0.7 9.2 ± 0.4 0.503 9.2 ± 0.7 9.2 ± 1.1 0.939
Phosphate (mg/dL) 4.0 ± 0.9 3.4 ± 0.8 0.007 4.8 ± 1.7 4.9 ± 1.8 0.902
iPTH (pg/dL) 61.9 ± 57.4 131.7 ± 159.4 0.027 170.6 ± 215.5 186.5 ± 284.9 0.693
CRP (mg/dL) 0.2 ± 0.3 0.2 ± 0.5 0.540 0.4 ± 0.9 0.6 ± 2.0 0.487
1,25(OH)2D (ng/mL) 36.0 ± 16.1 26.1 ± 9.0 0.004 23.7 ± 8.6 21.4 ± 8.3 0.107
25(OH)D (ng/mL) 19.4 ± 7.1 7.8 ± 2.2 < 0.001 15.9 ± 6.8 6.9 ± 1.7 < 0.001
Medications
ACEi/ARBs 80.4 100.0 0.789 67.4 73.4 0.560
Statin 51.6 48.4 0.801 40.8 51.4 0.206
Ca-containing P-binder 12.9 16.1 0.721 77.5 71.6 0.421
Data are presented as means ± SD or number of observations (%).
1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; ACEi, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor
blockers; BaPWV, brachial-ankle pulse wave velocity; BMI, body mass index; BUN, blood urea nitrogen; Ca-containing P-binder, calcium-containing
phosphate binder; CRP, C-reactive protein; CVD, cardiovascular disease; iPTH, intact parathyroid hormone; MDRD-4, estimated glomerular ﬁltration
rate estimated by Modiﬁcation of Diet in Renal Disease formula; PP, pulse pressure; SBP, systolic blood pressure; VD, vascular disease; WBC, white
blood cell.
Table 3. Causes of hospitalization during the follow-up period
Characteristics Predialysis patients (n) Dialysis patients (n)
Infectious/inﬂammatory 8 28
Cardiovascular 7 18
Cerebrovascular 0 8
GI bleeding 1 3
Other 12 22
Total 28 79
GI, gastrointestinal.
Figure 1. Serum 25(OH)D level associated with hospitalization-free survival
predialysis patients in relation to serum 25(OH)D (mean) 11.8 ng/mL or <
probability of dialysis patients in relation to serum 25(OH)D 9.6 ng/mL (mea
25(OH)D, 25-hydroxyvitamin D.
Ko et al / Serum 25(OH)D and survival in CKD 25period 2005e2013 [25]. Along with the increase in CKD prev-
alence, the economic costs resulting from the care of these
patients have increased. Medicare data from the United States
showed that in 2012, the annual expenditure spending for
patients with CKD was 24% of the total budget, a number
greater than that associated with chronic heart failure or dia-
betes [24]. Therefore, proper management of CKD patients is
required to improve clinical outcomes and reduce medical. (A) KaplaneMeier estimates of hospitalization-free survival probability of
11.8 ng/mL. (B) KaplaneMeier estimates of hospitalization-free survival
n) or <9.6 ng/mL.
Table 4. Univariate Cox proportional models for hospitalization
Characteristics Predialysis patients Dialysis patients
HR (95% CI) P HR (95% CI) P
Age (y) 1.000 (0.98e1.02) 0.991 1.024 (1.01e1.04) 0.007
Sex (female/male) 0.761 (0.49e1.18) 0.222 0.592 (0.38e0.92) 0.021
Diabetes (absent/present) 3.217 (2.00e5.18) < 0.001 2.374 (1.50e3.75) < 0.001
Coronary (absent/present) 13.631 (5.47e34.00) < 0.001 1.358 (0.78e2.35) 0.275
MDRD-4 (mL/min/1.73 m2) 0.982 (0.97e0.98) 0.014 e e
Albumin (g/dL) 0.579 (0.27e1.24) 0.160 0.677 (0.37e1.24) 0.677
Hemoglobin (g/dL) 0.776 (0.68e0.89) < 0.001 1.036 (0.97e1.11) 0.316
Calcium (mg/dL) 0.703 (0.47e1.06) 0.091 1.131 (0.86e1.49) 0.386
Phosphate (mg/dL) 1.485 (1.17e1.88) 0.001 0.995 (0.88e1.13) 0.944
iPTH (pg/dL) 1.001 (0.99e1.00) 0.227 0.999 (0.99e1.00) 0.108
CRP (mg/dL) 1.548 (0.95e2.51) 0.780 0.928 (0.76e1.13) 0.458
25(OH)D (ng/mL) 0.940 (0.91e0.97) 0.001 0.934 (0.89e0.97) 0.004
25(OH)D (below/above median) 0.624 (0.41e0.96) 0.033 0.536 (0.34e0.84) 0.007
25(OH)D, 25-hydroxyvitamin D; CI, conﬁdence interval; CRP, C-reactive protein; HR, hazard ratio; iPTH, intact parathyroid hormone; MDRD-4,
estimated glomerular ﬁltration rate estimated by Modiﬁcation of Diet in Renal Disease formula.
Table 5. Multivariate Cox proportional hazard models for hospitalization-free survival in predialysis and dialysis patients
Characteristics Predialysis patients Dialysis patients
HR (95% CI) P HR (95% CI) P
Age (y) e e 1.023 (1.00e1.04) 0.014
Sex (female/male) 0.808 (0.47e1.38) 0.440 0.767 (0.48e1.22) 0.260
Diabetes (absent/present) 3.579 (2.00e6.22) < 0.001 2.017 (1.27e3.21) 0.003
Coronary (absent/present) 31.719 (11.57e86.98) < 0.001 e e
MDRD-4 (mL/min/1.73 m2) 0.993 (0.96e1.02) 0.682 e e
Hemoglobin (g/dL) 0.945 (0.80e1.12) 0.519 e e
Phosphate (mg/dL) 1.090 (0.76e1.58) 0.625 e e
PTH 1.003 (1.01e1.05) 0.005 e e
25(OH)D (ng/mL) 0.963 (0.93e0.99) 0.039 0.955 (0.91e0.99) 0.040
25(OH)D, 25-hydroxyvitamin D; CI, conﬁdence interval; HR, hazard ratio; MDRD-4, estimated glomerular ﬁltration rate estimated by Modiﬁcation of
Diet in Renal Disease formula; PTH, parathyroid hormone.
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tionship between the serum level of 25(OH)D and hospitali-
zation in CKD patients could provide a basis and goal for
vitamin D supplement therapy among these patients.
It is well known that vitamin D deﬁciency is highly prevalent
among CKD patients [18e21]. The prevalence of hypovitami-
nosis, including insufﬁcient and deﬁcient serum 25(OH)D
levels, has been reported to be as high as 40% among CKD pa-
tients, although there are wide variations in reported preva-
lence depending on race, season, latitude, residual renal
function, and type of dialysis treatment [18e20]. Many factors
may contribute to low 25(OH)D levels in CKD, including loss of
vitamin Debinding proteins in the urine, ineffective vitamin D
synthesis in the skin on exposure to UV-B radiation, and
possibly reduced sun exposure and nutritional intake [21].
Moreover, an increase in the level of ﬁbroblast growth factor 23,
which can directly suppress the activity and expression of
1a-hydroxylase, decreases the vitamin D level during the
course of the disease [26]. Decreased expression of renal
megalin, which mediates the active process of endocytosis of
25(OH)D ﬁltered from the glomerular ultraﬁltrate, may further
reduce serum 25(OH)D concentrations in CKD patients [27]. It
can be inferred that an insufﬁcient serum vitamin D level and
low renal megalin expression result in a vicious negative
feedback cycle based on the function of 1,25(OH)2D3 as an
inducer of renal megalin [28].
In the hemodialysis (HEMO) study, which was designed to
examine the effect of dialysis dose and membrane ﬂux in 1,846
patients undergoing maintenance hemodialysis in the UnitedStates, participants with higher serum 25(OH)D levels were
younger, more frequently male, less likely to have diabetes, and
more likely to have higher serum albumin and calcium and
lower serum iPTH and high-sensitive C-reactive protein levels
than participants with lower serum 25(OH)D levels [15].
However, in our study, only male gender and diabetes were
signiﬁcantly different between dialysis patients with 25(OH)D
levels above or below themedian, possibly due to the small size
of our study cohort. In addition, arterial stiffness parameters
(PP and baPWV) had a tendency to be higher in the lower
25(OH)D groups among both predialysis and dialysis patients. A
larger study may be better able to elucidate 25(OH)D-associ-
ated variables in Asian CKD patients.
Insight into the nonhormonal, intracrine, and paracrine ac-
tions of vitamin D over the past few decades has resulted in a
new perspective on this vitamin [29]. In addition to being a
circulating regulator of mineral and skeletal homeostasis,
vitamin D has multifunctional roles in regulating innate im-
munity, blood pressure, cell proliferation, erythropoiesis, and
insulin resistance [28,30e32]. Actually, most tissues and cells in
the body have a VDR, and several contain 1a-hydroxylase,
which converts 25(OH)D into the active form 1,25(OH)2D3.
When toll-like receptors on monocyteemacrophages are
activated by pathogen-associated membrane patterns, such as
lipopolysaccharide, 1a-hydroxylase and VDR are upregulated,
and 25(OH)D is converted to 1,25(OH)2D3. Then, the
1,25(OH)2D3eVDReretinoid X receptor complex promotes the
expression of the cathelicidin antimicrobial gene in the nucleus
[29]. Recently, the association of upper respiratory infection
Ko et al / Serum 25(OH)D and survival in CKD 27and serum 25(OH)D has been demonstrated in both the general
population and CKD patients [14,15,33]. Interestingly,
1,25(OH)2D3-induced expression of cathelicidin antimicrobial
peptide has been reported in other tissues such as the gut,
placenta, and skin [34e36], which means vitamin D deﬁciency
could contribute to various infectious diseases.
The exact mechanism of the protective role of the 25(OH)D
level against cardiovascular disease is still under investigation.
However, clinical data have demonstrated that hypovitami-
nosis D is associatedwith hypertension, coronary heart disease,
congestive heart failure, and peripheral artery disease
[2,16,30,37]. London et al [38] reported that 25(OH)D and
1,25(OH)2D3 were negatively correlated with aortic pulse wave
velocity and positively correlated with brachial artery
distensibility and ﬂow-mediated dilatation in a cross-sectional
study of chronic hemodialysis patients. They proposed that
vitamin D deﬁciency could be associated with arteriosclerosis
and endothelial dysfunction in those patients [38]. The
renineangiotensinealdosterone system (RAS) is a hormone
system that regulates blood pressure and ﬂuid balance.
Angiotensin II, the main peptide of the RAS, is not only a
vasoactive hormone but also a regulator of cell proliferation
and/or apoptosis, ﬁbrosis, and a proinﬂammatory mediator
[39]. One mechanism by which vitamin D is cardiovascular
protective is through suppression of RAS because 1,25(OH)2D3
can inhibit renin synthesis in the kidney [2]. In our study, in-
fectious (33.6%) and cardiovascular (23.4%) diseases were the
most common causes of hospitalization (Table 3), which is
consistent with previous reports [9,14e16]. Among the various
extrarenal functions of vitamin D, its antimicrobial and car-
diovascular protective effects may lower hospitalization events
and promote longer hospitalization-free survival.
Although 1,25(OH)2D3 is the active form of vitamin D,
25(OH)D in the serum is the most plentiful and stable metab-
olite of vitamin D, so it is the best indicator of vitamin D status.
Compared with 25(OH)D, which has a half-life of 2e3 weeks,
circulating 1,25(OH)2D3 only has a half-life of 8e12 hours.
Furthermore, circulating 1,25(OH)2D3 concentration is only
one-thousandth of the 25(OH)D concentration and responds
rapidly to changes in calcium and phosphate metabolism [33].
Multiple observational studies have shown that a low 25(OH)D
level is associated with poor clinical outcomes in CKD and end
stage renal disease patients [9,14,15,20,40]. Several studies have
reported that 1,25(OH)2D3 is an independent predictor of
clinical outcome [9,40]. In our study, the 25(OH)D level was
signiﬁcantly correlated with hospitalization-free survival
(Table 5, Fig. 1), but the 1,25(OH)2D3 level was not (data not
shown). This ﬁnding may be because of the low concentration
and short half-life of 1,25(OH)2D3 in blood and the small size of
our study.
This study had several limitations. Only the baseline level of
serum 25(OH)D was measured, and changes in serum 25(OH)D
levels, which may affect hospitalization, were not recorded.
Fibroblast growth factor 23, cathelicidin, and rennin levels,
which can all affect vitamin D status and clinical outcomes,
were not examined. We were also not able to determine the
association between serum 25(OH)D levels and mortality
because of the low number of deaths during the follow-up
period.
Nevertheless, our study had several strengths. Serum
25(OH)D levels are affected by seasonal variations and the
assessment method. Here, we measured 25(OH)D levels of allthe participants during winter. Furthermore, patients who
received treatment with anticonvulsants or steroids, which
affect serum vitamin D levels, were excluded. The homogeneity
of the participants in each group was attributed to the single-
center nature of the study. Patients on hemodialysis for
>3 months at a frequency of 3 times/wk (>12 h/wk) who did
not undergo renal transplantation were selectively enrolled.
In conclusion, our ﬁndings suggest that the serum 25(OH)D
level is a predictor of hospitalization-free survival in CKD pa-
tients; vitamin D supplementation in these patients may
therefore improve clinical outcome.
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